SavedAdd your journal

Journals / Turkish Neurosurgery / 2018 / Cilt: 28 - Sayı: 6

A Novel Candidate Molecule in the Pathological Grading of Gliomas: ELABELA

Gökhan ARTAŞ
SAİT ÖZTÜRK
TUNCAY KULOĞLU
Adile Ferda DAĞLI
MURAT GÖNEN
HAKAN ARTAŞ
SÜLEYMAN AYDIN
FATİH SERHAT EROL
Pages
989–994
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies with a large number ofpatients are necessary to investigate the angiogenetic role of ELA in glial tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To investigate the possible role of ELABELA (ELA) in the histopathological grading of gliomas.MATERIAL and METHODS: We retrospectively assessed pathological specimens of patients who underwent surgery for intracranialspace-occupying lesions.
📊
Key Findings & Data:We enrolled 11 patients histologicallydiagnosed with low-grade glioma and 22 patients with high-grade glioma.
💡
Conclusion & Impact:Further studies with a large number ofpatients are necessary to investigate the angiogenetic role of ELA in glial tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

AIM: To investigate the possible role of ELABELA (ELA) in the histopathological grading of gliomas.MATERIAL and METHODS: We retrospectively assessed pathological specimens of patients who underwent surgery for intracranialspace-occupying lesions. Only primary glioma specimens were included in this study. We enrolled 11 patients histologicallydiagnosed with low-grade glioma and 22 patients with high-grade glioma. The ELA antibody was applied to 4–6-µm-thick sectionsobtained from paraffin blocks. Histoscores were calculated using the distribution and intensity of staining immunoreactivity. Anindependent sample t-test was used for two-point inter-group assessments, whereas one-way analysis of variance was used forthe other assessments. p<0.05 was considered statistically significant.RESULTS: The histoscores of the control brain, low-grade glioma, and high-grade glioma tissues were found to be 0.08, 0.37,and 0.92, respectively. The difference in ELA immunoreactivity between the control brain tissue and glioma tissue was statisticallysignificant (p<0.05). In addition, a statistically significant increase was observed in ELA immunoreactivity in high-grade gliomatissues compared with that in low-grade glioma tissues (p<0.05).CONCLUSION: ELA has an angiogenetic role in the progression of glial tumors. ELA, which is an endogenous ligand of the apelinreceptor, activates the apelinergic system and causes the progression of glial tumors. Further studies with a large number ofpatients are necessary to investigate the angiogenetic role of ELA in glial tumors.

🔖

Cite This Article

ARTAŞ, G., ÖZTÜRK, S., KULOĞLU, T., DAĞLI, A. F., GÖNEN, M., ARTAŞ, H., AYDIN, S., EROL, F. S. (2018). A Novel Candidate Molecule in the Pathological Grading of Gliomas: ELABELA. Turkish Neurosurgery, Cilt: 28 - Sayı: 6, 989–994. https://ajindex.com/articles/417671

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Alfarano C, Foussal C, Lairez O, Calise D, Attané C, Anesia R, Daviaud D, Wanecq E, Parini A, Valet P, Kunduzova O: Transition from metabolic adaptation to maladaptation of the heart in obesity: Role of apelin. Int J Obes (London) 39:312– 320, 2015
  2. Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, Vaudry H, Corvol P, Llorens-Cortes C: Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol 19:1015–1024, 2008
  3. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003 Bristol RE: Low-grade glial tumors: Are they all the same? Semin Pediatr Neurol 16:23-26, 2009
  4. Buckner JC, Brown PD, Brian P: Central Nervous System Tumors. Symposium on solid tumors. Mayo Clin Proc 82: 1271-1286, 2007
  5. Chapman NA, Dupré DJ, Rainey JK: The apelin receptor: Physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochem Cell Biol 92: 431–440, 2014
  6. Chng SC, Ho L, Tian J, Reversade B: ELABELA: A hormone essential for heart development signals via the apelin receptor. Dev Cell 27:672-680, 2013 Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), National Program of Cancer Registry of the United States. https://www.cdc.gov/ cancer/dcpc/data/index.htm (Accessed August 15, 2017)
  7. El Messari S, Iturrioz X, Fassot C, De Mota N, Roesch D, Llorens-Cortes C: Functional dissociation of apelin receptor signaling and endocytosis: Implications for the effects of apelin on arterial blood pressure. J Neurochem 90:1290–1301, 2004
  8. Galanth C, Hus-Citharel A, Li B, Llorens-Cortès C: Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr Pharm Des 18: 789–798, 2012
  9. Hao YZ, Li ML, Ning FL, Wang XW: APJ is associated with treatment response in gastric cancer patients receiving concurrent chemoradiotherapy and endostar therapy. Cancer Biother Radiopharm 32:133-138, 2017
  10. Harford-Wright E, Andre-Gregoire G, Jacobs KA, Treps L, Le Gonidec S, Leclair HM, Gonzalez-Diest S, Roux Q, Guillonneau F, Loussouarn D, Oliver L, Vallette FM, Foufelle F, Valet P, Davenport AP, Glen RC, Bidere N, Gavard J: Pharmacological targeting of apelin impairs glioblastoma growth. Brain 140:2939-2954, 2017
  11. Hinrichs BH, Newman S, Appin CL, Dunn W, Cooper L, Pauly R, Kowalski J, Rossi MR, Brat DJ: Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.